Astrana Health Q2 2026: The Growth Story Is Intact, the Margin Story Is Not

The headline numbers look like a company that's still flying. Q2 2026 revenue of $972.5 million, up 49% year-over-year. Adjusted EPS of $0.80, beating consensus. Net income more than doubling to $19.7 million. Adjusted EBITDA grew 43% to $68.9 million.

But the stock sold off 4.7% on the day and the first quarter's adjusted EBITDA guidance of $72.5 million to $77.5 million for Q3 implies a deceleration in growth rates that the factor stack has not yet been asked to price. That's the real question. Can a company growing revenue near 50% sustain it while adjusting to full-risk value-based care contracts and a material weakness in internal controls, or is the operating leverage story getting ahead of itself?

Valuation: 41.6x trailing earnings, 23.2x forward. The premium requires proof.

ASTH trades at a trailing P/E of 41.63 — the market is paying for roughly four years of current earnings power. The forward P/E of 23.19 is more defensible, but only if the earnings implied by that forward multiple actually materialize. For comparison, HCSG (Healthcare Services Group, a revenue-cycle management name in the same broader healthcare services space) trades at 12.3x trailing earnings and 0.81x trailing sales. CLOV (Clover Health, a closer business-model peer — also a Medicare Advantage risk-bearing platform) is still unprofitable at -43.3x trailing P/E but trades at 1.12x trailing sales. ASTH's price-to-sales ratio, worked off a market cap of $1.54 billion and $3.84 billion in trailing revenue, is roughly 0.40x — the cheapest multiple in this set on a sales basis.

So what does that mean? The P/S multiple tells you the market has already discounted ASTH's growth trajectory. The stock is not priced as a high-multiple growth darling despite 49% revenue growth. But that cheap sales multiple exists because the profit margins are razor-thin: 1.05% net margin, 3.12% operating margin. The market is saying the revenue growth is real but the conversion of that growth into durable profit power is still unproven.

Growth: 49% revenue growth is exceptional. The miss changes the context.

Revenue of $972.5 million missed Wall Street's estimate of roughly $985 million — a 1.3% shortfall. In a stock this small and this fast-growing, even a modest miss matters because it forces a conversation about the shape of the growth curve. The Q3 guidance midpoint of roughly $1.015 billion implies growth of about 6% year-over-year for the next quarter, down sharply from 49% in Q2. That deceleration is partly seasonal and partly the natural result of a larger base — but it means the second half has to do heavy lifting to hit the $3.8 billion to $4.1 billion full-year revenue range.

The first half of 2026 saw $1,937.6 million in revenue, up 52% year-over-year. That means the second half needs roughly $1.86 billion to $2.16 billion in revenue — or about $930 million to $1,080 million per quarter — to reach guidance. Q3's midpoint of $1.015 billion is comfortably inside that range, but it requires Q4 to finish near or above the Q3 midpoint as well. The arithmetic is achievable, but the margin for error is thin.

What's driving the growth? Approximately 80% of Care Partners revenue and 40% of owned membership are now in full-risk arrangements (where Astrana bears the downside if medical costs exceed the fixed payment, and shares upside if they come in under). The Texas Medicare Advantage agreement added roughly 3,000 new professional-risk lives. About 20,000 providers serve 1.5 million patients. The scale is real.

Margins: 7% adjusted EBITDA, flat year-over-year. That's the sticking point.

Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization — a rough proxy for cash earnings) came in at $68.9 million in Q2, or 7% of revenue. That's exactly flat versus the prior year's 7%. For a company growing revenue 49%, you'd expect at least some operating leverage — meaning EBITDA should grow faster than revenue as fixed costs are spread across more dollars of sales. The flat margin tells you the costs of expansion — full-risk transitions, the Prospect acquisition integration, the growing Care Delivery segment (which flipped to a $3 million operating loss) — are eating the leverage.

Even more striking is the free cash flow margin: 3% in Q2, down from 13.7% in the same quarter last year. On a year-to-date basis, operating cash flow was $100.8 million and free cash flow was $92.9 million, both below the prior year's pace. Management said they plan to reinvest the first-half outperformance into growth opportunities. That's a polite way of saying working capital and capex are front-loaded.

The raised full-year adjusted EBITDA guidance — midpoint of $267.5 million versus the prior $265 million midpoint — is a positive signal. It implies second-half EBITDA of roughly $132 million, meaning H2 needs to nearly double H1's $135.2 million. The guidance is bold and, if met, would push the full-year adjusted EBITDA margin above 7%.

Safety: $979 million in debt, $401 million in cash. The leverage math is the real risk.

Net debt sits at roughly $579 million. At the guidance midpoint for full-year EBITDA (using GAAP EBITDA proxy of $211 million to $236 million), the debt-to-EBITDA ratio would land around 4x to 4.5x on a trailing basis. Management cited pro forma net leverage of roughly 2.2x at the guidance midpoint — but that uses adjusted EBITDA, which excludes amortization, stock-based compensation, and acquisition-related costs. The GAAP-based leverage is notably higher.

Interest coverage of 1.39x means the company's EBIT just clears its interest payments. That's a tight number for a company that still needs to fund working capital for growth. Return on equity is 6.9%, return on invested capital is 6.69%. Both are modest. The capital structure is levered for a company that hasn't yet proven the durability of its margin expansion.

Add to that the material weakness in internal control over financial reporting, disclosed in the 10-K and acknowledged as a forward-looking risk factor in the press release. A material weakness means the company's auditors found deficiencies significant enough that a material misstatement could occur and not be caught. Management says remediation is underway, but until that's confirmed, the discount on the earnings numbers is justified.

Momentum: RSI at 26, well below the 50-day moving average. The technical picture is oversold, not strong.

The 14-day RSI sits at 26.36 — deep into oversold territory. The 50-day moving average is at $41.17, well above the current price of $34.13. The stock is below both short-term and medium-term trend lines. The MACD line is negative at -2.25. None of these signals are bullish.

That said, the 200-day moving average sits at $30.47, and the stock is still well above it. The 52-week move is up roughly 53%, so the pullback from a 50-day high is a correction within a broader uptrend. The RSI at 26 suggests the near-term selling has been excessive — but oversold is not the same as a buy signal. It means the stock can stay cheap for a while before it recovers.

What the factor stack says

Astrana's profile is a growth company wearing a value multiple. The cheap price-to-sales ratio reflects skepticism about margins, leverage, and the material weakness — all legitimate concerns. The growth factor is the strongest piece of the puzzle: 49% revenue growth, expanding full-risk footprint, 20,000 providers, 1.5 million patients. But growth without margin expansion is growth that doesn't compound. The flat 7% adjusted EBITDA margin and collapsing free cash flow margin are the factors that keep this from moving from Buy to Strong Buy.

The valuation is not expensive on a forward basis — 23x forward earnings is not a stretch for a company growing at this pace — but it's not cheap either. The stock trades at a discount to its own momentum narrative, which is what makes the technical oversold reading interesting. If the Q3 numbers show that the full-risk transition is stabilizing margins, the RSI and the price gap from the 50-day average could close fast. If they don't, the debt load and the material weakness will keep capping the multiple.

Portfolio role: Growth sleeve, high-conviction but wide-margin-of-error setup. The stock belongs in a growth allocation that can tolerate volatility, not in an income or stability sleeve. The specific trigger that changes the thesis is the next EBITDA margin read — if Q3 shows expansion above 7.5%, the factor stack turns more positive. If it stays flat or declines, the debt-to-EBITDA ratio becomes a harder constraint on the multiple. Watch the free cash flow margin too — a return toward the 10-13% range would validate that the working capital hit is temporary, not structural.

The six analyst price targets average $50.13, implying 47% upside from $34. Those targets are predicated on the guidance hitting its midpoint and margins improving. They're not conservative. The factor stack says the growth is credible, the valuation is tolerable, and the risk is in the margin trajectory and the balance sheet. That makes ASTH a barbell component — pair it with something durable and low-volatility if you're adding, because the leverage and the control weakness mean this is not a sit-in-a-chair name.